Lu, Diana Y.
Ellegast, Jana M.
Ross, Kenneth N.
Malone, Clare F.
Lin, Shan
Mabe, Nathaniel W. http://orcid.org/0000-0003-2675-652X
Dharia, Neekesh V. http://orcid.org/0000-0001-5048-067X
Meyer, Ashleigh
Conway, Amy
Su, Angela H.
Selich-Anderson, Julia
Taslim, Cenny
Byrum, Andrea K.
Seong, Bo Kyung A.
Adane, Biniam
Gray, Nathanael S. http://orcid.org/0000-0001-5354-7403
Rivera, Miguel N.
Lessnick, Stephen L. http://orcid.org/0000-0001-9645-4434
Stegmaier, Kimberly http://orcid.org/0000-0003-0218-7895
Article History
Received: 14 November 2021
Accepted: 24 November 2022
First Online: 19 January 2023
Competing interests
: K.S. receives grant funding from the DFCI/Novartis Drug Discovery Program and from KronosBio, is a member of the SAB and has stock options with Auron Therapeutics and has consulted for AstraZeneca. S.L.L. declares a competing interest as a member of the advisory board for Salarius Pharmaceuticals and is a listed the inventor on US patent no. US 7,939,253 B2, ‘Methods and compositions for the diagnosis and treatment of Ewing’s sarcoma’ and US patent no. US 8,557,532, ‘Diagnosis and treatment of drug-resistant Ewing’s sarcoma.’ N.V.D. is an employee of Genentech, a member of the Roche Group. N.S.G. is a founder, scientific advisory board member and equity holder in Syros, C4, Allorion, Jengu, B2S, Inception, EoCys, Larkspur (board member) and Soltego (board member). The remaining authors declare no competing interests.